Boston Biomedical, Inc.

Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company, founded in 2006, is a fully integrated oncology drug research and development company with a track record of accomplishments in advancing the research and development of multiple compounds and clinical programs. Its range of expertise includes drug discovery, external innovation partnerships, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs, and commercialization. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. has created a unique corporate environment, leveraging its innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for cancer. The company is indirectly and wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Additionally, in 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders, expanding its global oncology and hematology portfolios. As a venture capital firm, it's worth noting that the collaboration between Sumitomo Dainippon Pharma Co., Ltd., Boston Biomedical, and Tolero Pharmaceuticals demonstrates a strategic effort to expedite drug discovery, development, and commercialization of innovative treatments for cancer. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes. For more information, visit https://www.bostonbiomedical.com/careers/.